Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Sep 25. pii: mdz399. doi: 10.1093/annonc/mdz399. [Epub ahead of print]

PMID:
31553438
2.

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer.

Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

Sci Rep. 2019 Sep 16;9(1):13362. doi: 10.1038/s41598-019-50079-2.

3.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32481. [Epub ahead of print]

PMID:
31503343
4.

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).

Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, Takayama K, Hayashi H, Nakagawa Y, Kawakami T.

Clin Lung Cancer. 2019 Jul 31. pii: S1525-7304(19)30209-8. doi: 10.1016/j.cllc.2019.07.005. [Epub ahead of print]

PMID:
31466854
5.

Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.

Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T, Miura K, Matsuki T, Yamashita T, Omura G, Tsukahara K.

Acta Otolaryngol. 2019 Oct;139(10):918-925. doi: 10.1080/00016489.2019.1648867. Epub 2019 Aug 28.

PMID:
31460818
6.

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.

Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I.

Lung Cancer. 2019 Sep;135:145-150. doi: 10.1016/j.lungcan.2019.07.025. Epub 2019 Jul 24.

PMID:
31446987
7.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-1126. [Epub ahead of print]

PMID:
31439584
8.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS.

Respir Investig. 2019 Jul 31. pii: S2212-5345(18)30312-5. doi: 10.1016/j.resinv.2019.06.001. [Epub ahead of print] Review.

PMID:
31377122
9.

Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer.

Hihara K, Sato H, Okamoto I, Katsube Y, Maruyama R, Tomioka R, Tanaka H, Tsukahara K.

Auris Nasus Larynx. 2019 Dec;46(6):896-901. doi: 10.1016/j.anl.2019.02.005. Epub 2019 Jul 23.

PMID:
31350019
10.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

11.

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.

Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M.

PLoS One. 2019 Jun 4;14(6):e0217991. doi: 10.1371/journal.pone.0217991. eCollection 2019.

12.

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).

Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K.

Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5.

PMID:
31097081
13.

N-Ethynylation of Anilides Decreases the Double-Bond Character of Amide Bond while Retaining trans-Conformation and Planarity.

Yamasaki R, Morita K, Iizumi H, Ito A, Fukuda K, Okamoto I.

Chemistry. 2019 Aug 1;25(43):10118-10122. doi: 10.1002/chem.201901451. Epub 2019 Jun 26.

PMID:
31050845
14.

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).

Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K.

Lung Cancer. 2019 May;131:128-133. doi: 10.1016/j.lungcan.2019.03.021. Epub 2019 Mar 22.

15.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.

Oncologist. 2019 Aug;24(8):1022-1026. doi: 10.1634/theoncologist.2019-0101. Epub 2019 Apr 25.

PMID:
31023862
16.

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.

Park K, Wan-Teck Lim D, Okamoto I, Yang JC.

Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374. doi: 10.1177/1758835919836374. eCollection 2019. Review.

17.

A symmetric toggle switch explains the onset of random X inactivation in different mammals.

Mutzel V, Okamoto I, Dunkel I, Saitou M, Giorgetti L, Heard E, Schulz EG.

Nat Struct Mol Biol. 2019 May;26(5):350-360. doi: 10.1038/s41594-019-0214-1. Epub 2019 Apr 8.

18.

Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.

Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, Nakanishi Y, Okamoto I.

Lung Cancer. 2019 Apr;130:5-9. doi: 10.1016/j.lungcan.2019.01.014. Epub 2019 Jan 29.

PMID:
30885351
19.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

20.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
21.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
22.

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.

Sato H, Tsukahara K, Okamoto I, Katsube Y, Shimizu A, Kondo T, Hanyu K, Fushimi C, Okada T, Miura K.

Acta Otolaryngol. 2019 Feb;139(2):201-205. doi: 10.1080/00016489.2018.1551623. Epub 2019 Feb 22.

PMID:
30794080
23.

Post-operative complications of salvage total laryngectomy forpost-radiotherapy recurrent laryngeal cancer using pectoralis major myocutaneous flaps.

Okamoto I, Tsukahara K, Shimizu A, Sato H.

Acta Otolaryngol. 2019 Feb;139(2):167-171. doi: 10.1080/00016489.2018.1532108. Epub 2019 Feb 22.

PMID:
30794035
24.

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.

Hino T, Kamitani T, Sagiyama K, Yamasaki Y, Okamoto I, Tagawa T, Ijichi K, Yamamoto H, Yabuuchi H, Honda H.

Eur J Radiol Open. 2019 Jan 31;6:72-77. doi: 10.1016/j.ejro.2019.01.006. eCollection 2019.

25.

Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.

Kubo N, Harada T, Shiraishi Y, Nosaki K, Nakagaki N, Takeshita M, Ouchi H, Iwama E, Tanaka K, Okamoto I, Sasaki H, Nakanishi Y.

Anticancer Res. 2019 Feb;39(2):671-677. doi: 10.21873/anticanres.13162.

PMID:
30711944
26.

Classification of tumors by imaging diagnosis and preoperative fine-needle aspiration cytology in 120 patients with tumors in the parapharyngeal space.

Matsuki T, Miura K, Tada Y, Masubuchi T, Fushimi C, Kanno C, Takahashi H, Kamata S, Okamoto I, Miyamoto S, Yamashita T.

Head Neck. 2019 May;41(5):1277-1281. doi: 10.1002/hed.25552. Epub 2019 Jan 8.

PMID:
30620436
27.

Risk Factors of Subsequent Primary Melanomas in Austria.

Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2019 Feb 1;155(2):188-195. doi: 10.1001/jamadermatol.2018.4645.

PMID:
30566178
28.

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.

Anai S, Iwama E, Yoneshima Y, Otsubo K, Tanaka K, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Dec;126:156-161. doi: 10.1016/j.lungcan.2018.11.002. Epub 2018 Nov 5.

PMID:
30527181
29.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

30.

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.

Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18.

PMID:
30429011
31.

Decision-making for people with dementia and advanced kidney disease: a secondary qualitative analysis of interviews from the Conservative Kidney Management Assessment of Practice Patterns Study.

Scott J, Owen-Smith A, Tonkin-Crine S, Rayner H, Roderick P, Okamoto I, Leydon G, Caskey F, Methven S.

BMJ Open. 2018 Nov 12;8(11):e022385. doi: 10.1136/bmjopen-2018-022385.

32.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

33.

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients.

Nogami N, Nishio M, Okamoto I, Enatsu S, Suzukawa K, Takai H, Nakagawa K, Tamura T.

Respir Investig. 2019 Jan;57(1):27-33. doi: 10.1016/j.resinv.2018.09.003. Epub 2018 Oct 4.

PMID:
30293944
34.

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer Sci. 2018 Dec;109(12):3921-3933. doi: 10.1111/cas.13820. Epub 2018 Nov 13.

35.

Structural and functional analysis of miraculin-like protein from Vitis vinifera.

Ohkura SI, Hori M, Saitoh K, Okuzawa T, Okamoto I, Furukawa N, Shimizu-Ibuka A.

Biochim Biophys Acta Proteins Proteom. 2018 Nov;1866(11):1125-1130. doi: 10.1016/j.bbapap.2018.08.009. Epub 2018 Aug 27.

PMID:
30282610
36.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
37.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
38.

Prevention of anastomotic leak using an advanced pectoral flap in total pharyngolaryngectomy and free jejunal reconstruction for hypopharyngeal or laryngeal carcinoma.

Kondo T, Tsukahara K, Yoshizawa N, Okamoto I, Motohashi R, Nomoto M, Katsube Y, Yatomi M, Iwasawa T, Hanyu K, Ogawa Y.

Acta Otolaryngol. 2018 Oct;138(10):951-955. doi: 10.1080/00016489.2018.1492152. Epub 2018 Sep 27.

PMID:
30261803
39.

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.

Kimura S, Tanaka K, Harada T, Liu R, Shibahara D, Kawano Y, Nakanishi Y, Okamoto I.

Cancer Sci. 2018 Nov;109(11):3657-3661. doi: 10.1111/cas.13787. Epub 2018 Sep 25.

40.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.

PMID:
30240852
41.

Generation of human oogonia from induced pluripotent stem cells in vitro.

Yamashiro C, Sasaki K, Yabuta Y, Kojima Y, Nakamura T, Okamoto I, Yokobayashi S, Murase Y, Ishikura Y, Shirane K, Sasaki H, Yamamoto T, Saitou M.

Science. 2018 Oct 19;362(6412):356-360. doi: 10.1126/science.aat1674. Epub 2018 Sep 20.

PMID:
30237246
42.

Combined Immunofluorescence, RNA FISH, and DNA FISH in Preimplantation Mouse Embryos.

Okamoto I.

Methods Mol Biol. 2018;1861:149-159. doi: 10.1007/978-1-4939-8766-5_12.

PMID:
30218366
43.

Spontaneous and Direct Transformation of N,O-Diaryl Carbamates into N,N'-Diarylureas.

Yamasaki R, Honjo Y, Ito A, Fukuda K, Okamoto I.

Chem Pharm Bull (Tokyo). 2018;66(9):880-884. doi: 10.1248/cpb.c18-00394.

44.

Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma.

Sato H, Yoshimasu S, Okamoto I, Shimizu A, Katsube Y, Tanaka H, Tsukahara K.

Case Rep Otolaryngol. 2018 Jul 31;2018:1463218. doi: 10.1155/2018/1463218. eCollection 2018.

45.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
46.

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I.

Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28.

47.

Reuse of intermittent catheters: a qualitative study of IC users' perspectives.

Avery M, Prieto J, Okamoto I, Cullen S, Clancy B, Moore KN, Macaulay M, Fader M.

BMJ Open. 2018 Aug 17;8(8):e021554. doi: 10.1136/bmjopen-2018-021554.

48.

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade.

Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Oncotarget. 2018 Jul 17;9(55):30587-30593. doi: 10.18632/oncotarget.25743. eCollection 2018 Jul 17.

49.

Contributions by MC1R Variants to Melanoma Risk in Males and Females.

Wendt J, Mueller C, Rauscher S, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2018 Jul 1;154(7):789-795. doi: 10.1001/jamadermatol.2018.1252.

50.

A Case of Septicemia due to Nonocclusive Mesenteric Ischemia Occurring in Induction Chemotherapy.

Tanaka H, Tsukahara K, Okamoto I, Kojima R, Hirasawa K, Sato H.

Case Rep Otolaryngol. 2018 Apr 19;2018:7426819. doi: 10.1155/2018/7426819. eCollection 2018.

Supplemental Content

Loading ...
Support Center